Skip to main content

Abbvie Value Stock - Dividend - Research Selection


ISIN: US00287Y1091, WKN: A1J84E

Market price date: 22.05.2020
Market price: 92,10 USD

Abbvie Fundamental data and company key figures of the share

Annual reports in USD
Key figures 25-02-2020
Cash flow
Net operating cash flow 13.324.000.000
Capital Expenditures -552.000.000
Free cash flow 12.771.999.744
Balance sheet
Total Equity -
Liabilities & Shareholders equity
Income statement
Net income 7.882.000.000
Eps (diluted) 5,280
Diluted shares outstanding 1.492.800.000
Net sales/revenue

Fundamental ratios calculated on: 22-05-2020

Key figures 22-05-2020
Cash flow
P/C 10,32
P/FC 10,77
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization137.486.876.672,00 USD
CountryUnited States
IndicesRussell 3000,S&P 500
SectorsHealth service
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines, including more than 50 investigational programs in clinical development across such important medical specialties as immunology, virology, oncology and neurology, with additional targeted investment in cystic fibrosis and women's health.


AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.


On June 1, 2016, AbbVie acquired all of the outstanding equity interests in Stemcentrx, Inc. (Stemcentrx), a privately held biotechnology company. The aggregate upfront consideration paid by AbbVie in connection with the acquisition was approximately $5.8 billion. The transaction expands AbbVie’s oncology pipeline by adding the late-stage asset rovalpituzumab tesirine (Rova-T), four additional early-stage clinical compounds in solid tumor indications and a significant portfolio of pre-clinical assets. Rova-T is currently in registrational trials for small cell lung cancer and in early-stage clinical development for other solid tumors.



AbbVie operates in one business segment—pharmaceutical products. See Note 15 to the Consolidated Financial Statements and the sales information related to HUMIRA included under Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations."

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,